Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balsano

Showing results (391-400 of 408) with videos related to

Pageof 41
Sort By:
Journal of Hepatology|December 28, 2025
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA)Virginia Genovesi, Francesca Salani, Margherita Rimini, et al.
Gut|September 1, 2025
Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcomeGiulia Milardi, Barbara Franceschini, Chiara Camisaschi, et al.
Targeted Oncology|February 12, 2024
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus DurvalumabMargherita Rimini, Eleonora Loi, Mario Domenico Rizzato, et al.
Medicina|January 22, 2021
COVID-19 with and without pneumonia: clinical outcomes in the internal medicine wardSantiago E Melendi, María M Pérez, Cintia E Salas, et al.
Targeted Oncology|May 1, 2024
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyMargherita Rimini, Gianluca Masi, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|April 8, 2022
SPINE20 recommendations 2021: spine care for people's health and prosperityGiuseppe Costanzo, Bernardo Misaggi, Luca Ricciardi, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.
Pageof 41

Showing results (391-400 of 408) with videos related to

Sort By:
Pageof 41
Journal of Hepatology|December 28, 2025
Molecular profiling and matched targeted treatment in cholangiocarcinoma: results from the Italian dataset (ANITA)Virginia Genovesi, Francesca Salani, Margherita Rimini, et al.
Gut|September 1, 2025
Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcomeGiulia Milardi, Barbara Franceschini, Chiara Camisaschi, et al.
Targeted Oncology|February 12, 2024
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus DurvalumabMargherita Rimini, Eleonora Loi, Mario Domenico Rizzato, et al.
Medicina|January 22, 2021
COVID-19 with and without pneumonia: clinical outcomes in the internal medicine wardSantiago E Melendi, María M Pérez, Cintia E Salas, et al.
Targeted Oncology|May 1, 2024
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyMargherita Rimini, Gianluca Masi, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|April 8, 2022
SPINE20 recommendations 2021: spine care for people's health and prosperityGiuseppe Costanzo, Bernardo Misaggi, Luca Ricciardi, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
International Journal of Cancer|July 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Silvia Camera, et al.
Pageof 41